Full-Time
Confirmed live in the last 24 hours
Supports genomics startups through funding and resources
Entry
Company Historically Provides H1B Sponsorship
Cambridge, UK
The role is a 12-month placement starting in July 2025, finishing July 2026, and is based at the offices in Granta Park, Cambridge.
You match the following Illumina's candidate preferences
Employers are more likely to interview you if you match these preferences:
Illumina focuses on building a supportive environment for startups in the genomics field. Their main initiative, Illumina Accelerator, helps entrepreneurs create and grow genomics companies by providing funding and resources. The accelerator is located in both the San Francisco Bay Area and Cambridge, UK, and has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from other accelerators is its strong partnership with leading venture capital investors and its specific focus on the genomics industry. The goal of Illumina is to foster innovation and growth in genomics, ultimately advancing the field and its applications.
Company Size
5,001-10,000
Company Stage
IPO
Total Funding
$27.2M
Headquarters
San Diego, California
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three yearsSAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the longstanding partners will set the standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years
Broad Institute to collaborate on flagship project tapping Illumina's new spatial technologyAt AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brainsCompany expands software portfolio to decode multimodal data with Illumina Connected MultiomicsSAN DIEGO, Feb. 19, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. These capabilities are expected to drive expansion of spatial research and unlock applications and experiments that were previously not possible.Illumina has announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Details and early access customer data will be presented next week during Illumina’s Gold Sponsor Workshop at the Advances in Genome Biology and Technology General Meeting in Florida.Details and early access customer data will be presented next week during Illumina's Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) General Meeting in Florida."Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms," said Steve Barnard, PhD, chief technology officer of Illumina
SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference.The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer).Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – (https://illumina-agbt-investor-session-feb-2025.open-exchange.net/) To ensure timely connection, please join at least ten minutes before the scheduled start of the session.A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter) , Facebook , LinkedIn , Instagram , TikTok , and YouTube .Investors:Salli Schwartz+1.858.291.6421[email protected]Media:Bonny Fowler+1.740.641.5579[email protected]SOURCE Illumina, Inc
Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.
This week in artificial intelligence, President Joe Biden issued executive orders related to AI leadership and safety while Nvidia unveiled partnerships with healthcare organizations to accelerate drug discovery. OpenAI, Amazon and Elon Musk were also in the news. Biden’s Executive Orders Focus on Governance, Safety. President Joe Biden issued executive orders related to maintaining leadership of AI in the United States and policies to protect against potential AI harms